Semaglutide linked to lower psychiatric hospitalization risk in bipolar patients

Semaglutide, the active ingredient in the weight‑loss and diabetes drugs Ozempic and Wegovy, has shown a potential benefit for people with bipolar disorder, according to a large Swedish study. Researchers followed almost 15,000 individuals with the condition and found that those who used semaglutide experienced a 21 % reduction in the risk of psychiatric hospitalization compared with non‑users.

The investigators suggest that semaglutide’s influence on inflammation and brain‑related biological pathways may help stabilize mood. Interestingly, other glucagon‑like peptide‑1 (GLP‑1) receptor agonists did not demonstrate a similar association, indicating a possible unique effect of semaglutide. The study adds to a growing body of evidence that medications originally developed for metabolic disorders can have broader therapeutic applications.

While the findings are promising, the researchers caution that further studies are needed to confirm the mechanism and to evaluate long‑term safety in bipolar patients. If confirmed, semaglutide could represent a novel adjunctive treatment option for reducing severe mood episodes in this population.